Literature DB >> 8912547

Prospective evaluation of prognostic factors in operable breast cancer.

R A Hawkins1, A L Tesdale, M E Killen, W J Jack, U Chetty, J M Dixon, M J Hulme, R J Prescott, M A McIntyre, W R Miller.   

Abstract

In 215 patients with operable breast cancer (T1-T3, N0-1, M0) and no other or previous cancer, presenting to a single breast unit, sufficient tumour was available for the prospective determination of four putative biochemical markers of prognosis: oestrogen receptor (ER) activity, cathepsin D (cath D), epidermal growth factor receptor (EGFR) activity and cyclic AMP-binding proteins (c-AMP-b). There were significant inter-relationships between ER and EGFR (r = -0.26), c-AMP-b and cath D (r = +0.32) and ER and c-AMP-b (r = +0.14). After follow-up (median 36.2 months), a total of 55 recurrences (18 locoregional only) and 35 deaths were recorded. By univariate analysis, up to 10 of 18 biochemical, clinical and histopathological variables of potential prognostic value were significantly related to disease-free interval or death, but by multivariate analysis only oestrogen receptor concentration and node status contributed significantly to risk of both distant recurrence/death; in addition, tumour size made a small contribution to the risk for a distant recurrence only. Only two parameters, tumour grade and ER concentration, were significantly related to risk of locoregional recurrence by univariate analysis, but by multivariate analysis, only tumour grade was important. It is concluded that tumour ER concentration, axillary nodal status and tumour grade remain as the most important prognostic factors in the early years after presentation of operable breast cancer, with a minor influence of tumour size. At this time, the prognostic significance of quantitative measurements of ER concentration, carefully controlled for the quality of both assay and tumour specimen, is probably greater than is generally appreciated. We have yet to identify other factors, which add significantly to the short-term prognostic value of these key features.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8912547      PMCID: PMC2074769          DOI: 10.1038/bjc.1996.567

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  37 in total

1.  Prognostic factors for breast cancer: have they met their promise?

Authors:  C K Osborne
Journal:  J Clin Oncol       Date:  1992-05       Impact factor: 44.544

2.  Epidermal growth factor receptors in human breast cancer: a plea for standardisation of assay methodology.

Authors:  P G Koenders; D Faverly; L V Beex; E D Bruggink; C B Kienhuis; T J Benraad
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

3.  Pathological features predictive of local recurrence after management by conservation of invasive breast cancer: importance of non-invasive carcinoma.

Authors:  D A Paterson; T J Anderson; W J Jack; G R Kerr; A Rodger; U Chetty
Journal:  Radiother Oncol       Date:  1992-11       Impact factor: 6.280

4.  Evolution of immunoreactivity of monoclonal antibodies H222 and/or D547 used in the detection of breast cancer estrogen receptors. Varying reactivity of receptor isoforms.

Authors:  H Cren; C Lechevrel; G Roussel; J Goussard
Journal:  J Steroid Biochem Mol Biol       Date:  1991-10       Impact factor: 4.292

5.  The role of cathepsin D in the invasiveness of human breast cancer cells.

Authors:  M D Johnson; J A Torri; M E Lippman; R B Dickson
Journal:  Cancer Res       Date:  1993-02-15       Impact factor: 12.701

6.  Cytosol protein content and prognosis in operable breast cancer. Correlations with steroid hormone receptors and other prognostic factors.

Authors:  J A Søreide; O A Lea; S Kvinnsland
Journal:  Breast Cancer Res Treat       Date:  1991-12       Impact factor: 4.872

7.  Cyclic AMP binding proteins and prognosis in breast cancer.

Authors:  W R Miller; R A Elton; J M Dixon; U Chetty; D M Watson
Journal:  Br J Cancer       Date:  1990-02       Impact factor: 7.640

8.  Epidermal growth factor receptors in intracranial and breast tumours: their clinical significance.

Authors:  R A Hawkins; E Killen; I R Whittle; W J Jack; U Chetty; R J Prescott
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

9.  Categorising continuous variables.

Authors:  D G Altman
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

10.  Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer.

Authors:  G Gasparini; P Bevilacqua; F Pozza; S Meli; P Boracchi; E Marubini; J R Sainsbury
Journal:  Br J Cancer       Date:  1992-11       Impact factor: 7.640

View more
  4 in total

Review 1.  The EGF receptor family--multiple roles in proliferation, differentiation, and neoplasia with an emphasis on HER4.

Authors:  H Shelton Earp; Benjamin F Calvo; Carolyn I Sartor
Journal:  Trans Am Clin Climatol Assoc       Date:  2003

2.  Immunocytochemical assessment of sigma-1 receptor and human sterol isomerase in breast cancer and their relationship with a series of prognostic factors.

Authors:  J Simony-Lafontaine; M Esslimani; E Bribes; S Gourgou; N Lequeux; R Lavail; J Grenier; A Kramar; P Casellas
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

3.  Human dyskerin binds to cytoplasmic H/ACA-box-containing transcripts affecting nuclear hormone receptor dependence.

Authors:  Federico Zacchini; Giulia Venturi; Veronica De Sanctis; Roberto Bertorelli; Claudio Ceccarelli; Donatella Santini; Mario Taffurelli; Marianna Penzo; Davide Treré; Alberto Inga; Erik Dassi; Lorenzo Montanaro
Journal:  Genome Biol       Date:  2022-08-22       Impact factor: 17.906

4.  Outcome after extended follow-up in a prospective study of operable breast cancer: key factors and a prognostic index.

Authors:  R A Hawkins; A L Tesdale; R J Prescott; T Forster; M A McIntyre; P Baker; W J L Jack; U Chetty; J M Dixon; M E Killen; M J Hulme; W R Miller
Journal:  Br J Cancer       Date:  2002-07-01       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.